Additionally, multiomics studies in GBM have reported several therapy targets, such as EGFR variation, BRAF mutation and NTRK fusions, and multi-arm trials that include molecular biomarkers are recommended in the design of a high-efficiency clinical trial (8, 69). This evidence concerns the gene BRAF and glioblastoma.